BirchBioMed Inc.
Carlos Camozzi is an experienced executive in the biopharmaceutical industry, currently serving as CEO and Founder of CRC - Management Consulting GmbH since October 2018. Camozzi holds multiple leadership roles, including Chief Medical Officer at BirchBioMed Inc. and ADYA, where responsibilities involve advancing clinical programs and regulatory strategies for innovative therapies. As Chairperson of the Rare and Orphan Advisory Board at Simbec-Orion, Camozzi leads discussions among experts in rare diseases. Additionally, contributions to organizations such as GettingUp.Org and the RE(ACT) Discovery Institute reflect a commitment to patient advocacy and funding for orphan drug research. With a medical background as a Clinical Pharmacologist, Paediatrician, and MD from reputable institutions, Camozzi has significant expertise in orphan drugs and rare diseases, demonstrated through roles with multiple companies and advisory positions since 2016.
This person is not in any teams
This person is not in any offices
BirchBioMed Inc.
BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation. A University of British Columbia (“UBC”) spin-off, BirchBioMed holds the exclusive, worldwide pharmaceutical license from UBC for two medical therapeutic technologies that mark significant medical breakthroughs in the treatment of fibrosis and certain autoimmune diseases. Initially funded by key strategic donors and government bodies, including the Canadian Institute of Health Research and the Natural Sciences and Engineering Research Council of Canada (the Canadian counterpart of the U.S. National Institutes of Health), BirchBioMed's licensed technology has secured more than $6 million in government and association grants, coupled with additional university resources. It is also the first technology that UBC has advanced from discovery through Phase I clinical trials with support strictly from government/private donations.